Abstract:Abstract The development of castration-resistant prostate cancer after androgen deprivation therapy remains the major challenge in the treatment of advanced prostate cancer. Current androgen deprivation therapy targets the action of androgen receptor by reducing circulating androgen level through castration or by disrupting the binding of androgens to the receptor with anti-androgen. Despite the initial efficacy of androgen deprivation therapy, relapse with incurable castration-resistant prostate cancer invariably occurs, constituting the major cause of prostate cancer mortality. Although castration-resistant prostate cancer is no longer responsive to androgen deprivation, the expression and signaling of androgen receptor are maintained. Agents such as abiraterone are effective in prolonging survival in patients with castration-resistant prostate cancer, but even this potent and irreversible CYP17 inhibitor has a relatively short time to disease progression in these patients. One potential mechanism is the prevalent upregulation of the constitutively-active, ligand-binding-domain-truncated androgen receptor splice variants, which have been shown to contribute to castration-resistant tumor growth. Thus, developing effective strategies attacking the androgen receptor itself to reduce its availability is urgently needed in the battle against prostate cancer recurrence during androgen deprivation therapy. Our data show that two potent second-generation selenium-containing drugs, methylseleninic acid (MSA) and methylselenocysteine (MSC), are very effective in decreasing the abundance of both the full-length and the truncated androgen receptor. They not only enhance the efficacy of anti-androgen in both androgen-dependent and castration-resistant prostate cancer cells, but also inhibit prostate tumor relapse after castration in a xenograft model. Our results also show that combination of these agents with anti-androgen produces a robust downregulation of an androgen receptor target, telomerase and its catalytic subunit, telomere reverse transcriptase (hTERT). The combination efficacy is significantly mitigated when hTERT/telomerase expression is restored. In addition, their inhibition of prostate tumor relapse after castration is also accompanied by a pronounced decrease of hTERT. The importance of the findings on hTERT/telomerase lies not only in its key role in regulating cell growth and survival, but also in the association of high hTERT expression with biochemical recurrence in prostate cancer patients undergoing radical prostatectomy and neoadjuvant androgen deprivation therapy. Taken together, our findings provide strong justification and lay the groundwork for an effective therapeutic modality that capitalizes on a new approach of disrupting androgen-receptor-mediated growth response important for the development of castration resistance. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4557. doi:10.1158/1538-7445.AM2011-4557

Abstract 2910: Selenium Nanoparticles Suppress Prostate LNCaP Cancer Cells Growth Through Induced Endogenous Apoptosis

The Suppression of Prostate LNCaP Cancer Cells Growth by Selenium Nanoparticles Through Akt/Mdm2/AR Controlled Apoptosis.

Selenium nanoparticles (SeNPs) have potent antitumor activity against prostate cancer cells through the upregulation of miR-16

Abstract 4557: A Novel Approach of Disrupting Androgen-Receptor Signaling for Prostate Cancer Intervention

Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition

Functionalized Selenium Nanotherapeutics Synergizes with Zoledronic Acid to Suppress Prostate Cancer Cell Growth Through Induction of Mitochondria-Mediated Apoptosis and Cell Cycle S Phase Arrest.

Prostate Specific Antigen Expression is Down-Regulated by Selenium Through Disruption of Androgen Receptor Signaling.

Abstract 1264: Studying Senescence in Prostate of Selenium Treated Rats Undergoing Carcinogen-Induced, Androgen-Promoted Prostate Carcinogenesis

Monomethylated Selenium Inhibits Growth of LNCaP Human Prostate Cancer Xenograft Accompanied by a Decrease in the Expression of Androgen Receptor and Prostate-Specific Antigen (PSA)

Enhancing Radiotherapy Sensitivity in Prostate Cancer with Lentinan-Functionalized Selenium Nanoparticles: Mechanistic Insights and Therapeutic Potential

Inorganic Selenium Induces Nonapoptotic Programmed Cell Death in PC-3 Prostate Cancer Cells Associated with Inhibition of Glycolysis.

Selenium Decreases Prostate Specific Antigen Expression by Inducing Protein Degradation and Suppressing Mrna Abundance

Androgen Receptor Signaling Intensity Is A Key Factor In Determining The Sensitivity Of Prostate Cancer Cells To Selenium Inhibition Of Growth And Cancer-Specific Biomarkers

Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer.

Selenium in Prostate Cancer: Prevention, Progression, and Treatment

Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells

Abstract 191: Methylseleninic acid super-activates p53 senescence axis as a preventive barrier to prostate tumorigenesis driven by Pten deficiencyin vivo.

Selenium-Containing Amphiphiles Reduced and Stabilized Gold Nanoparticles: Kill Cancer Cells via Reactive Oxygen Species.

N-Acetyl-l-cysteine Enhances the Effect of Selenium Nanoparticles on Cancer Cytotoxicity by Increasing the Production of Selenium-Induced Reactive Oxygen Species.

Abstract C023: P21-positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy

Delineation Of The Molecular Basis For Selenium-Induced Growth Arrest In Human Prostate Cancer Cells By Oligonucleotide Array